MX2015005352A - Composiciones y métodos para el tratamiento de la enfermedad de parkinson mediante la administración selectiva de moléculas de oligonucleótidos a tipos específicos de neuronas. - Google Patents
Composiciones y métodos para el tratamiento de la enfermedad de parkinson mediante la administración selectiva de moléculas de oligonucleótidos a tipos específicos de neuronas.Info
- Publication number
- MX2015005352A MX2015005352A MX2015005352A MX2015005352A MX2015005352A MX 2015005352 A MX2015005352 A MX 2015005352A MX 2015005352 A MX2015005352 A MX 2015005352A MX 2015005352 A MX2015005352 A MX 2015005352A MX 2015005352 A MX2015005352 A MX 2015005352A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- transporter
- compositions
- nucleic acid
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261719284P | 2012-10-26 | 2012-10-26 | |
| EP12382414 | 2012-10-26 | ||
| PCT/EP2013/072410 WO2014064257A1 (en) | 2012-10-26 | 2013-10-25 | Compositions and methods for the treatment of parkinson disease by the selective delivery of oligonucleotide molecules to specific neuron types |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015005352A true MX2015005352A (es) | 2015-10-29 |
Family
ID=47148690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015005352A MX2015005352A (es) | 2012-10-26 | 2013-10-25 | Composiciones y métodos para el tratamiento de la enfermedad de parkinson mediante la administración selectiva de moléculas de oligonucleótidos a tipos específicos de neuronas. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9084825B2 (https=) |
| EP (1) | EP2911695B1 (https=) |
| JP (1) | JP6386461B2 (https=) |
| CN (1) | CN104884094A (https=) |
| AU (1) | AU2013336581A1 (https=) |
| CA (1) | CA2890112A1 (https=) |
| ES (1) | ES2967530T3 (https=) |
| HK (1) | HK1214179A1 (https=) |
| MX (1) | MX2015005352A (https=) |
| WO (1) | WO2014064257A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2796722C (en) | 2010-04-19 | 2021-06-01 | Nlife Therapeutics, S.L. | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types |
| CA2817960C (en) | 2010-11-17 | 2020-06-09 | Ionis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
| CN107115352B (zh) | 2011-08-04 | 2020-10-30 | 耶达研究及发展有限公司 | 微rna和包含微rna的组合物 |
| EP2911695B1 (en) | 2012-10-26 | 2023-11-29 | Palomo Limited | Compositions and methods for the treatment of parkinson disease by the selective delivery of oligonucleotide molecules to specific neuron types |
| CA2936158C (en) | 2014-02-05 | 2023-06-13 | Yeda Research And Development Co. Ltd. | Use of mir-135 or precursor thereof for the treatment and diagnosis of a bipolar disease |
| US11426366B2 (en) | 2015-05-15 | 2022-08-30 | Arizona Board Of Regents On Behalf Of The Universsity Of Arizona | Compositions and methods for treating motor disorders |
| IL320434A (en) | 2015-07-22 | 2025-06-01 | Wave Life Sciences Ltd | Oligonucleotide preparations and methods |
| US10733023B1 (en) * | 2015-08-06 | 2020-08-04 | D2Iq, Inc. | Oversubscription scheduling |
| WO2017119463A1 (ja) * | 2016-01-07 | 2017-07-13 | 国立大学法人大阪大学 | α－シヌクレイン発現抑制剤 |
| JP2019513371A (ja) | 2016-04-01 | 2019-05-30 | アビディティー バイオサイエンシーズ エルエルシー | 核酸ポリペプチド組成物とその使用 |
| WO2019009299A1 (ja) * | 2017-07-05 | 2019-01-10 | 国立大学法人大阪大学 | α－シヌクレイン発現抑制するＥＮＡアンチセンスオリゴヌクレオチド |
| WO2019009298A1 (ja) * | 2017-07-05 | 2019-01-10 | 国立大学法人大阪大学 | α－シヌクレイン発現抑制剤 |
| KR101890925B1 (ko) | 2017-08-08 | 2018-08-24 | 주식회사 이레산업 | 캠핑용 그릴 세트 |
| EP3691657A4 (en) * | 2017-10-04 | 2021-07-21 | Avidity Biosciences, Inc. | NUCLEIC ACID POLYPEPTIDE COMPOSITIONS AND USES THEREOF |
| WO2019079887A1 (en) * | 2017-10-23 | 2019-05-02 | Carleton University | APTAMERS AS A THERAPEUTIC TO PREVENT AGGREGATION OF PROTEINS IN NEURODEGENERATIVE DISEASE |
| TWI809004B (zh) * | 2017-11-09 | 2023-07-21 | 美商Ionis製藥公司 | 用於降低snca表現之化合物及方法 |
| SG11202006528XA (en) | 2018-01-12 | 2020-08-28 | Bristol Myers Squibb Co | Antisense oligonucleotides targeting alpha-synuclein and uses thereof |
| SG11202006142PA (en) | 2018-01-12 | 2020-07-29 | Roche Innovation Ct Copenhagen As | Alpha-synuclein antisense oligonucleotides and uses thereof |
| CN119264211A (zh) | 2018-08-27 | 2025-01-07 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
| WO2020106859A1 (en) * | 2018-11-21 | 2020-05-28 | University Georgia Research Foundation, Inc., | Bimodal nanoparticle conjugates for non-invasive central nervous system tissue imaging |
| AU2019390097A1 (en) * | 2018-11-30 | 2021-07-15 | Kyowa Kirin Co., Ltd. | Nucleic acid conjugate |
| US12478684B2 (en) | 2019-04-11 | 2025-11-25 | Northeastern University | Oligonucleotide-polymer miktoarm conjugates and methods of use |
| US12006499B2 (en) | 2019-06-06 | 2024-06-11 | Avidity Biosciences, Inc. | Una amidites and uses thereof |
| US20220390443A1 (en) * | 2019-11-11 | 2022-12-08 | Oxford University Innovation Limited | Method of isolating a selected population of exosomes |
| CN115168823B (zh) * | 2022-08-05 | 2025-07-18 | 聊城大学 | 基于组平均的多任务功能性近红外光谱信号的身份识别 |
| WO2024166019A1 (en) * | 2023-02-08 | 2024-08-15 | Biorchestra Co., Ltd. | Sirna targeting alpha-synuclein and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL66831A0 (en) | 1981-10-05 | 1982-12-31 | Kefalas As | Indane derivatives |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| US6455736B1 (en) | 1994-12-16 | 2002-09-24 | Uop Llc | Process for preparation of pharmaceutically desired sertraline and sertraline analogs |
| WO1997026270A2 (en) | 1996-01-16 | 1997-07-24 | Ribozyme Pharmaceuticals, Inc. | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules |
| WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| WO2005004794A2 (en) * | 2003-06-09 | 2005-01-20 | Alnylam Pharmaceuticals Inc. | Method of treating neurodegenerative disease |
| JP2007525211A (ja) * | 2004-01-19 | 2007-09-06 | テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド | パーキンソン病の診断検査 |
| WO2007050789A2 (en) * | 2005-10-25 | 2007-05-03 | Nëdken Corporation | Glycosyl-oligonucleotide conjugates and methods |
| GB0605337D0 (en) | 2006-03-17 | 2006-04-26 | Genomica Sau | Treatment of CNS conditions |
| US20090176729A1 (en) * | 2007-12-14 | 2009-07-09 | Alnylam Pharmaceuticals, Inc. | Method of treating neurodegenerative disease |
| BRPI0821310A2 (pt) | 2007-12-20 | 2015-06-16 | Angiochem Inc | Conjugados polipeptídeos-ácido nucleico e usos dos mesmos |
| US9255266B2 (en) * | 2009-05-06 | 2016-02-09 | Rutgers, The State University Of New Jersey | RNA targeting in alpha-synucleinopathies |
| WO2011087804A2 (en) | 2009-12-21 | 2011-07-21 | Medtronic, Inc. | Peptide-polynucleotide compositions, and methods for transfecting a cell with dna and treatment of neurodegenerative disease |
| CA2796722C (en) * | 2010-04-19 | 2021-06-01 | Nlife Therapeutics, S.L. | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types |
| WO2012027713A2 (en) * | 2010-08-26 | 2012-03-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of snca |
| CA2817960C (en) * | 2010-11-17 | 2020-06-09 | Ionis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
| AU2013336582A1 (en) | 2012-10-26 | 2015-06-11 | Nlife Therapeutics, S.L. | Compositions and methods for selective delivery of oligonucleotide molecules to cell types |
| EP2911695B1 (en) | 2012-10-26 | 2023-11-29 | Palomo Limited | Compositions and methods for the treatment of parkinson disease by the selective delivery of oligonucleotide molecules to specific neuron types |
-
2013
- 2013-10-25 EP EP13783061.8A patent/EP2911695B1/en active Active
- 2013-10-25 AU AU2013336581A patent/AU2013336581A1/en not_active Abandoned
- 2013-10-25 WO PCT/EP2013/072410 patent/WO2014064257A1/en not_active Ceased
- 2013-10-25 CN CN201380068146.3A patent/CN104884094A/zh active Pending
- 2013-10-25 HK HK16102420.8A patent/HK1214179A1/zh unknown
- 2013-10-25 MX MX2015005352A patent/MX2015005352A/es unknown
- 2013-10-25 CA CA2890112A patent/CA2890112A1/en not_active Abandoned
- 2013-10-25 ES ES13783061T patent/ES2967530T3/es active Active
- 2013-10-25 JP JP2015538467A patent/JP6386461B2/ja active Active
- 2013-10-28 US US14/065,024 patent/US9084825B2/en active Active - Reinstated
-
2015
- 2015-07-20 US US14/803,811 patent/US10125363B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2967530T3 (es) | 2024-04-30 |
| EP2911695C0 (en) | 2023-11-29 |
| WO2014064257A1 (en) | 2014-05-01 |
| JP2015536927A (ja) | 2015-12-24 |
| CA2890112A1 (en) | 2014-05-01 |
| AU2013336581A1 (en) | 2015-06-11 |
| US20140120158A1 (en) | 2014-05-01 |
| HK1214179A1 (zh) | 2016-07-22 |
| US10125363B2 (en) | 2018-11-13 |
| JP6386461B2 (ja) | 2018-09-05 |
| US9084825B2 (en) | 2015-07-21 |
| EP2911695B1 (en) | 2023-11-29 |
| EP2911695A1 (en) | 2015-09-02 |
| CN104884094A (zh) | 2015-09-02 |
| US20160083726A1 (en) | 2016-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015005352A (es) | Composiciones y métodos para el tratamiento de la enfermedad de parkinson mediante la administración selectiva de moléculas de oligonucleótidos a tipos específicos de neuronas. | |
| WO2011131693A3 (en) | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types | |
| CY1121198T1 (el) | Αντινοημaτικα μορια και μεθοδοι για την θεραπεια παθολογιων | |
| WO2012036433A3 (ko) | miRNA를 타겟으로 한 신경퇴행성 질환 치료 | |
| MX2015005328A (es) | Composiciones y metodos para la administracion selectiva de moleculas de oligonucleotidos a tipos de celulas. | |
| UA115122C2 (uk) | Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським | |
| WO2011020783A3 (en) | Targeted immunoconjugates | |
| JO3764B1 (ar) | جزيئات إرتباط il-18 | |
| EA032867B9 (ru) | Оптимизированная с помощью эндосомолитических средств система доставки in vivo конъюгатов нуклеиновой кислоты | |
| BR112012024710A8 (pt) | moléculas que se ligam ao antígeno, seus processos de produção, bem como composição farmacêutica que as compreendem | |
| MX356625B (es) | Oligonucleotidos para elaborar un cambio en la secuencia de una molécula de ácido ribonucleico objetivo presente en una célula viva. | |
| BR112013005699A2 (pt) | moléculas de ligação a 4-1bb | |
| BR112012020705A2 (pt) | axmi221z, axmi222z, axmi224z, e axmi225z genes de delta-endotoxina e métodos para sua utilização. | |
| MX374906B (es) | Nuevos inmunoconjugados | |
| PH12014502141A1 (en) | New indanyloxydihydrobenzofuranylacetic acid derivatives and their use as gpr40 receptor agonists | |
| MX2015018049A (es) | Funcionalizacion de superficies sin catalizador e injerto de polimeros. | |
| WO2012075040A3 (en) | mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES | |
| MX358321B (es) | Anticuerpos anti-ceacam5 y usos de los mismos. | |
| MY171038A (en) | Bispecific antigen binding molecules | |
| EA201590783A1 (ru) | Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma | |
| WO2012024396A3 (en) | Compositions and methods for delivering nucleic acid molecules and treating cancer | |
| MX360179B (es) | Complejo nanomolecular nts-poliplex que comprende el gen bdnf, para usarse en el tratamiento de la enfermedad de parkinson y composiciones farmacéuticas que lo contienen. | |
| EA201000238A1 (ru) | Антигенсвязывающие белки для il-18 рецептора и их применение | |
| PH12013502568B1 (en) | Anti-psgl-1 antibodies and uses thereof | |
| WO2013170272A3 (en) | Site-specific labeling and targeted delivery of proteins for the treatment of cancer |